AbbVie Inc. $ABBV Stock Position Decreased by Alps Advisors Inc.

Alps Advisors Inc. cut its holdings in AbbVie Inc. (NYSE:ABBV) by 26.7% in the third quarter, HoldingsChannel reports. The firm owned 121,867 shares of the company’s stock after selling 44,294 shares during the period. Alps Advisors Inc.’s holdings in AbbVie were worth $28,217,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Conning Inc. increased its stake in shares of AbbVie by 7.1% in the 2nd quarter. Conning Inc. now owns 191,023 shares of the company’s stock valued at $35,458,000 after purchasing an additional 12,690 shares during the last quarter. Diversified Trust Co boosted its stake in AbbVie by 23.6% in the third quarter. Diversified Trust Co now owns 57,076 shares of the company’s stock valued at $13,215,000 after buying an additional 10,891 shares in the last quarter. Permanent Capital Management LP bought a new position in AbbVie in the third quarter valued at about $720,000. Railway Pension Investments Ltd raised its stake in AbbVie by 33.0% during the third quarter. Railway Pension Investments Ltd now owns 853,949 shares of the company’s stock worth $197,723,000 after acquiring an additional 211,800 shares in the last quarter. Finally, World Investment Advisors raised its stake in AbbVie by 9.4% during the third quarter. World Investment Advisors now owns 113,925 shares of the company’s stock worth $26,378,000 after acquiring an additional 9,811 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

ABBV has been the topic of a number of research reports. Guggenheim boosted their target price on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research note on Monday, October 20th. Berenberg Bank set a $275.00 price objective on AbbVie in a research report on Tuesday, January 20th. BMO Capital Markets reiterated an “outperform” rating and issued a $258.00 target price on shares of AbbVie in a research report on Thursday, January 15th. Sanford C. Bernstein restated a “market perform” rating on shares of AbbVie in a report on Thursday. Finally, Raymond James Financial set a $256.00 price objective on AbbVie in a research note on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $251.00.

Key AbbVie News

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Morgan Stanley raised its price target to $270 and kept an “overweight” call, signaling institutional analyst conviction that AbbVie has double‑digit upside from current levels. Read More.
• Positive Sentiment: Company forecasts for full‑year 2026 profit came in above estimates, driven by strong sales of newer immunology drugs (Skyrizi, Rinvoq), supporting the case for continued top‑line and earnings growth. Read More.
• Positive Sentiment: Market commentary and some analysts view the post‑earnings pullback as a buying opportunity, pointing to institutional accumulation, durable cash flow, and a strong dividend as anchors for medium‑term returns. Read More.
• Positive Sentiment: New real‑world Rinvoq data from Japan bolsters the drug’s addressable market for ankylosing spondylitis and reinforces growth prospects for AbbVie’s immunology franchise. Read More.
• Neutral Sentiment: Management framed the earnings call around “new growth engines” — Skyrizi/Rinvoq and other launches taking the lead in driving growth, which supports the long‑term story but doesn’t eliminate near‑term volatility. Read More.
• Neutral Sentiment: Q4 results beat on revenue and showed strong margin/earnings leverage, confirming product momentum even as some segments face headwinds. Read More.
• Negative Sentiment: Shares initially gapped down after the print as investors focused on a softer-than‑expected Q1 EPS and revenue outlook despite the quarter’s beats — a classic near‑term reaction to guidance misses. Read More.
• Negative Sentiment: AbbVie set Q1 2026 EPS guidance at $2.97–$3.01 (vs. ~3.11 consensus) and gave revenue guidance below the street, creating short‑term uncertainty about the cadence of 2026 growth. Read More.
• Negative Sentiment: Broader coverage highlighted investor “angst” and a bifurcated reaction — bullish on medium‑term fundamentals but worried about near‑term comps and valuation — keeping volatility elevated. Read More.

AbbVie Trading Up 2.0%

Shares of ABBV stock opened at $223.50 on Friday. The firm has a fifty day simple moving average of $223.74 and a two-hundred day simple moving average of $219.63. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The firm has a market capitalization of $395.01 billion, a PE ratio of 94.70, a price-to-earnings-growth ratio of 0.91 and a beta of 0.35.

AbbVie (NYSE:ABBV) last posted its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a negative return on equity of 4,184.47% and a net margin of 6.91%.The company had revenue of $16.62 billion for the quarter, compared to analyst estimates of $16.39 billion. During the same quarter last year, the company earned $2.16 earnings per share. The company’s revenue for the quarter was up 10.0% on a year-over-year basis. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. On average, equities analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.